Investigational New Drug CDMO Market to Record 12.9% CAGR Through 2030

SHARE THIS ARTICLE

The global Investigational New Drug CDMO market size is expected to be worth around US$ 13.8 billion by 2030, according to a new report by Vision Research Reports.

The global Investigational New Drug CDMO market size was valued at US$ 9.2 billion in 2020 and is anticipated to grow at a CAGR of 12.9% during forecast period 2021 to 2030.

Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@ https://www.visionresearchreports.com/report/sample/38506

Investigational New Drug CDMO Market (By Product: Small Molecule, Large Molecule; By Service: Contract Development, Contract Manufacturing; By End-use: Pharmaceutical Companies, Biotech Companies, Others (Government, Research Institutes, Academic Institutes, etc.)) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

Report Coverage

Report Scope Details
Market Size USD 13.8 billion by 2030
Growth Rate CAGR of 12.9% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Product, Service, End-user
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Lonza; Catalent; Recipharm AB; Siegfried Holding AG; Thermo Fisher Scientific Inc.; Covance Inc.; Charles River Laboratories; Cambrex Corporation; IQVIA Holdings Inc.; Syneous Health

Growth Factors

 The market growth can be attributed to factors such as the increasing outsourcing services by pharmaceutical companies, rising R&D investments, and stringent regulations for conducting clinical studies. The FDA’s role in the development of a novel drug begins when the drug’s sponsor decides to test the new molecule’s diagnostic or therapeutic potential in humans after screening it for pharmacological activity and acute toxicity potential in animals. The molecule then changes its legal position under the Federal Food, Drug, and Cosmetic Act, becoming a new drug subject to the drug regulatory system’s specific requirements.

Report Highlights

The small molecule segment held the largest share of 90.0% in 2020 and is likely to remain dominant over the forecast period. This is largely due to the increasing number of small molecules in development. Small molecules constitute more than 100% of the drugs currently in the market.

The large molecule segment is anticipated to register the fastest CAGR of 10.8% throughout the forecast period. This is largely due to pharmaceutical and biotech companies investing more in the discovery and development of large molecule therapeutic proteins due to their specificity, which allows for the targeting of previously difficult-to-address conditions in disease states, such as oncology, neurology, and metabolic disease.

The contract development segment dominated the market with a revenue share of 95.5% in 2020. The segment is also projected to expand at the fastest CAGR during the forecast period. The contract development offers several benefits over in-house development of drugs, such as access to industry experts, less time to market, cost-effectiveness, and more focus on core competencies.

The pharmaceutical companies segment led the market and accounted for 79.4% in 2020. This can be attributed to the increasing investments in the pharmaceutical sector. There are roughly 7,000 different rare diseases that impact 350 million people worldwide, and more research is being done than ever before.

The biotech companies segment is anticipated to register a lucrative growth rate of 10.0% over the forecast period. The basic research is carried out both independently and in collaboration with researchers and others from various parts of the biomedical research ecosystem, such as disease foundations and patient organizations, venture capital, and pre-competitive consortia.

North America held the largest share of 51.1% in 2020. This can be attributed to the increased R&D investments by life sciences and pharmaceutical companies, which are expected to boost the demand for contract manufacturing in the region. In the U.S, it takes an investigational drug an average of 12 years to get from the lab to the medicine cabinet.

Key Players

  • Covance Inc.
  • Charles River Laboratories Inc.
  • Cambrex Corporation
  • IQVIA Holdings Inc.
  • Syneos Health
  • Lonza
  • Catalent
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.

Market Segmentation

  • Product
    • Small Molecule
    • Large Molecule
  • Service
    • Contract Development
      • Small Molecule
        • Bioanalysis and DMPK Studies
        • Toxicology Testing
        • Pathology and Safety Pharmacology Studies
        • Drug Substance Synthetic Route Development
        • Drug Substance Process Development
        • Form Selection Crystallization Process Development
        • Scale-up of Drug Substance
        • Pre Formulation
        • Preclinical Formulation Selection
        • First In Man Formulation/ Process Development
        • Analytical Method Development / Validation
        • Release Testing of Drug Substance and Drug Product
        • Work Up Purification Steps
        • Telescoping & Process Refining
        • Initial Optimization
        • Formal Stability of Drug Substance and Drug Product
      • Large Molecule
        • Cell Line Development
        • Process Development
          • Upstream
            • Microbial
            • Mammalian
            • Others
          • Downstream
            • MABs
            • Recombinant Proteins
            • Others
    • Contract Manufacturing
      • Small Molecule
        • Oral Solids
        • Liquid and Semi-solids
        • Injectables
        • Others
      • Large Molecule
        • MABs
        • Recombinant Proteins
        • Others
  • End-user
    • Pharmaceutical Companies
    • Biotech Companies
    • Others (Government, Research Institutes, Academic Institutes, etc.)
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38506 or call: +1 9197 992 333

Daksh

Daksh is an SEO Analyst having 3 years of experienced. we can quickly understand and support initiatives that will contribute to the goals and success of client campaigns. and also Perform keyword research in coordination with client business objectives to optimize existing content and uncover new opportunities.

View all posts by Daksh →

Leave a Reply

Your email address will not be published.